

ADDENDUM DATED 12 DECEMBER 2024

THIS ADDENDUM IS IMPORTANT AND REQUIRES YOUR IMMEDIATE ATTENTION. PLEASE READ IT CAREFULLY.

IF YOU ARE IN ANY DOUBT AS TO THE ACTION YOU SHOULD TAKE, YOU SHOULD CONSULT YOUR STOCKBROKER, BANK MANAGER, SOLICITOR, ACCOUNTANT, TAX ADVISER OR OTHER PROFESSIONAL ADVISER IMMEDIATELY.

This Addendum, together with the Annual Report of Singapore Institute of Advanced Medicine Holdings Ltd. (the “**Company**”, and together with its subsidiaries, the “**Group**”) for the financial year ended 30 June 2024, the notice of annual general meeting (the “**AGM**”) and the accompanying proxy form, has been made available to the shareholders of the Company (the “**Shareholders**”) on the SGXNET at <https://www.sgx.com/securities/company-announcements> and the Company’s website at <https://www.advancedmedicine.sg/>. Its purpose is to explain to Shareholders the relevant information relating to, and to seek Shareholders’ approval for the Proposed Appointment of Auditors (as defined herein) to be tabled at the AGM of the Company to be held at 1 Biopolis Drive, Amnios, Singapore 138622, Level 2, Auditorium on Friday, 27 December 2024 at 2.30 p.m. or at any adjournment thereof.

A printed copy of this Addendum and the Annual Report will NOT be despatched to Shareholders. Printed copies of the notice of AGM and the accompanying proxy form will be despatched to shareholders.

If you have sold or transferred all your shares in the capital of the Company held through The Central Depository (Pte) Limited (“**CDP**”), you need not forward the notice of AGM and the accompanying proxy form to the purchaser or transferee as arrangements will be made by CDP for a separate notice of AGM and accompanying proxy form to be sent to the purchaser or transferee. If you have sold or transferred all your shares in the capital of the Company represented by physical share certificate(s), you should immediately forward the notice of AGM and the accompanying proxy form to the purchaser or transferee, or to the bank, stockbroker or agent through whom the sale or the transfer was effected for onward transmission to the purchaser or transferee. You should also inform the purchaser or transferee, or the bank, stockbroker or other agent through whom the sale or transfer was effected for onward notification to the purchaser, that this Addendum, together with the Annual Report of the Company, the notice of AGM and the accompanying Proxy Form, may be accessed on the SGXNET at <https://www.sgx.com/securities/company-announcements> and the Company’s website at <https://www.advancedmedicine.sg/>.

*The Company was listed on Catalist of the Singapore Exchange Securities Trading Limited (“**SGX-ST**”) on 16 February 2024. The initial public offering of the Company was sponsored by PrimePartners Corporate Finance Pte. Ltd. (the “**Sponsor**”).*

This Addendum has not been examined or approved by the SGX-ST. The SGX-ST assumes no responsibility for the contents of this document, including the correctness of any of the statements or opinions made or reports contained in this Addendum.

The contact person for the Sponsor is Ms. Ng Shi Qing, 16 Collyer Quay, #10-00 Collyer Quay Centre, Singapore 049318, sponsorship@ppcf.com.sg.



SINGAPORE INSTITUTE OF ADVANCED MEDICINE HOLDINGS LTD.

(Incorporated in the Republic of Singapore on 24 November 2011)
(Company Registration Number: 201134046D)

ADDENDUM TO THE ANNUAL REPORT IN RELATION TO

THE PROPOSED CHANGE OF AUDITORS OF THE COMPANY FROM MESSRS PRICEWATERHOUSECOOPERS LLP TO MESSRS FOO KON TAN LLP

IMPORTANT DATES AND TIMES

Last date and time for lodgement of Proxy Form	:	24 December 2024 at 2.30 p.m.
Date and time of AGM	:	27 December 2024 at 2.30 p.m.
Place of AGM	:	1 Biopolis Drive, Amnios, Singapore 138622, Level 2, Auditorium

CONTENTS

	PAGE
DEFINITIONS	2
LETTER TO SHAREHOLDERS	
1. INTRODUCTION	5
2. PROPOSED CHANGE OF AUDITORS OF THE COMPANY FROM MESSRS PRICEWATERHOUSECOOPERS LLP TO MESSRS FOO KON TAN LLP	5
3. INTERESTS OF DIRECTORS AND SUBSTANTIAL SHAREHOLDERS	10
4. DIRECTORS' RECOMMENDATION	11
5. DIRECTORS' RESPONSIBILITY STATEMENT	12
6. DOCUMENTS FOR INSPECTION	12
APPENDIX A – FKT CONSENT LETTER	A-1

DEFINITIONS

In this Addendum, the following definitions shall apply throughout unless the context otherwise requires or otherwise stated:

“ACRA”	:	The Accounting and Corporate Regulatory Authority of Singapore
“Addendum”	:	This addendum to Shareholders dated 12 December 2024
“AGM”	:	The annual general meeting of the Company to be held on 27 December 2024 at 2.30 p.m.
“Audit Committee”	:	The audit committee of the Company as at the Latest Practicable Date, comprising Mr Gurdip Singh S/O Boor Singh, Mr Khoo Tiam Hock Vernon and Dato’ Lee Kok Chuan
“Auditors”	:	The external auditors of the Company as appointed from time to time
“Board” or “Directors”	:	The board of Directors of the Company as at the Latest Practicable Date
“Catalist”	:	The sponsor-supervised listing platform of the SGX-ST
“Catalist Rules”	:	The Listing Manual Section B: Rules of Catalist of the SGX-ST, as amended, modified or supplemented from time to time
“CDP”	:	The Central Depository (Pte) Limited
“Companies Act”	:	The Companies Act 1967 of Singapore, as amended, modified or supplemented from time to time
“Company”	:	Singapore Institute of Advanced Medicine Holdings Ltd.
“Constitution”	:	The constitution of the Company, as amended or modified from time to time
“Directors”	:	The directors of the Company as at the Latest Practicable Date
“FKT”	:	Foo Kon Tan LLP
“FY”	:	Financial year of the Company ended or ending 30 June (as the case may be)
“Group”	:	The Company and its subsidiaries, collectively

DEFINITIONS

<i>“HY”</i>	:	6-month financial period of the Company ended or ending 31 December (as the case may be)
<i>“Latest Practicable Date”</i>	:	21 November 2024, being the latest practicable date prior to the printing of this Addendum
<i>“PwC”</i>	:	PricewaterhouseCoopers LLP
<i>“Proposed Appointment of Auditors”</i>	:	The proposed appointment of FKT as Auditors in place of the retiring Auditors, PwC
<i>“Proxy Form”</i>	:	The proxy form in respect of the AGM enclosed with the notice of AGM and the Annual Report
<i>“Securities Account”</i>	:	The securities account maintained by a Depositor with CDP (but does not include a securities sub-account maintained with a Depository Agent)
<i>“SFA”</i>	:	The Securities and Futures Act 2001 of Singapore, as amended, modified or supplemented from time to time
<i>“SGX-ST”</i>	:	Singapore Exchange Securities Trading Limited
<i>“Share(s)”</i>	:	Ordinary share(s) in the capital of the Company
<i>“Share Capital”</i>	:	The issued and paid-up share capital of the Company
<i>“Shareholders”</i>	:	The registered holders of the Shares in the register of members of the Company, except where the registered holder is CDP, the term “Shareholders” shall, in relation to such Shares and where the context so admits, mean the Depositors whose Securities Accounts are credited with such Shares
<i>“Sponsor”</i>	:	PrimePartners Corporate Finance Pte. Ltd.
<i>“SRS”</i>	:	Supplementary Retirement Scheme
<i>“SRS Investors”</i>	:	Investors who have purchased Shares using their respective SRS contributions and which Shares are held on their behalf by SRS Operators
<i>“SRS Operators”</i>	:	Approved agent banks for SRS Investors
<i>“Substantial Shareholder”</i>	:	A person (including a corporation) who holds directly or indirectly 5% or more of the total issued voting Shares

DEFINITIONS

Currencies, Units and Others

“%” : Per centum or percentage

“S\$” or “cents” : Singapore dollars and cents, respectively

The terms “**Depositor**”, “**Depository Agent**” and “**Depository Register**” shall have the same meanings ascribed to them respectively in Section 81SF of the SFA. The term “**subsidiary**” shall have the same meaning ascribed to it in Section 5 of the Companies Act.

Words importing the singular shall, where applicable, include the plural and *vice versa*, and words importing the masculine gender shall, where applicable, include the feminine and neuter genders and *vice versa*. References to persons shall include corporations.

Any reference in this Addendum to any statute or enactment is a reference to that statute or enactment as for the time being amended or re-enacted. Any word or term defined under the Companies Act, the SFA, the Catalist Rules or any statutory modification thereof and used in this Addendum shall, where applicable, have the same meaning ascribed to it under the Companies Act, the SFA, the Catalist Rules or any statutory modification thereof, as the case may be, unless otherwise provided.

Any reference in this Addendum to shares being allotted to a person includes allotment to CDP for the account of that person.

Any reference to a time of day and to dates in this Addendum shall be a reference to Singapore time and dates, unless otherwise stated.

The headings in this Addendum are inserted for convenience only and shall be ignored in construing this Addendum.

Any discrepancies in this Addendum between the sum of the figures stated and the total thereof are due to rounding. Accordingly, figures shown as totals in this Addendum may not be an arithmetic aggregation of the figures which precede them.

Opal Lawyers LLC has been appointed as the legal adviser to the Company as to Singapore law in relation to this Addendum.

LETTER TO SHAREHOLDERS

SINGAPORE INSTITUTE OF ADVANCED MEDICINE HOLDINGS LTD.

(Company Registration Number 201134046D)
(Incorporated in the Republic of Singapore)

Board of Directors

Khoo Tiam Hock Vernon (*Chairman and Independent Director*)
Dr Djeng Shih Kien (*Executive Director and Chief Executive Officer*)
Yeo Seng Lye Paul (*Executive Director and Chief Operating Officer*)
Vivienne Cheng Chi Fan (*Non-Executive and Non-Independent Director*)
Dato' Lee Kok Chuan (*Non-Executive and Non-Independent Director*)
Gurdip Singh S/O Boor Singh @ Gurdip Singh Khaira (*Independent Director*)
Sumei Shum (*Independent Director*)

Registered Office

1 Biopolis Drive,
#02-01, Amnios,
Singapore 138622

12 December 2024

To: The Shareholders of Singapore Institute of Advanced Medicine Holdings Ltd.

Dear Sir/Madam,

PROPOSED CHANGE OF AUDITORS OF THE COMPANY FROM MESSRS PRICEWATERHOUSECOOPERS LLP TO MESSRS FOO KON TAN LLP

1. INTRODUCTION

- 1.1 The Directors refer to the notice of AGM of the Company dated 12 December 2024 (the “**Notice of AGM**”) convening the AGM of the Company to be held on 27 December 2024.
- 1.2 The proposed Ordinary Resolution 7 in the Notice of AGM relates to the proposed appointment of Messrs Foo Kon Tan LLP as the Auditors in place of the retiring Auditors, Messrs PricewaterhouseCoopers LLP, to hold office until the conclusion of the next AGM and to authorise the Directors of the Company to fix their remuneration.
- 1.3 The purpose of this Addendum is to provide Shareholders with the relevant information pertaining to, explain the rationale for, and to seek Shareholders’ approval for, for the resolution in respect of the Proposed Appointment of Auditors to be tabled at the AGM.
- 1.4 The SGX-ST assumes no responsibility for the accuracy of any statements or opinions made or reports contained in this Addendum. If a Shareholder is in any doubt as to the course of action he should take, he should consult his bank manager, stockbroker, solicitor, accountant, tax adviser or other professional adviser(s) immediately.

2. PROPOSED CHANGE OF AUDITORS OF THE COMPANY FROM MESSRS PRICEWATERHOUSECOOPERS LLP TO MESSRS FOO KON TAN LLP

2.1 Background and rationale for the Proposed Appointment of Auditors

The ordinary resolution proposed in the Notice of AGM is to appoint Messrs Foo Kon Tan LLP (“**FKT**”) as the auditors of the Company in place of the retiring auditors, PricewaterhouseCoopers LLP (“**PwC**”), and to authorise the Directors to fix its remuneration.

LETTER TO SHAREHOLDERS

The Company's current auditors, PwC, were re-appointed as auditors of the Company at the Company's last annual general meeting held on 15 December 2023, to hold office until the conclusion of the next AGM. PwC has served as auditors of the Company for 6 years, before the Company's listing on the Catalist board of the SGX-ST in 2024.

As part of the Group's ongoing efforts to manage its overall business costs and expenses amidst the challenging business climate, the Board is of the view that it would be appropriate and timely to effect a change of auditors with effect from the current financial year ending 30 June 2025 ("FY2025"), subject to Shareholders' approval via ordinary resolution proposed in the Notice of AGM. The Board is of the view that a change of auditors is in the best interests of the Company and its Shareholders as (i) the quantum of professional fees for the audit services proposed by other audit firms is more competitive given a comparable scope of work, and (ii) it will also enable the Company to benefit from fresh perspectives and views of another professional audit firm to enhance the value of the audit services, thereby according the Group an opportunity to benchmark audit fees with a view to realising cost efficiencies without any reduction in the scope of audit. The Directors believe that the Proposed Appointment of Auditors will allow the Company to save in audit fees, amounting to a difference of approximately S\$100,000, based on the proposed audit fees for FY2025. The outgoing Auditor, PwC, has also, by way of a letter dated 9 December 2024, indicated that it will not be seeking re-appointment at the forthcoming AGM.

Accordingly, the Audit Committee and the Board have interviewed and engaged with various reputable audit firms in Singapore, which are qualified and have experience in auditing public listed companies on the SGX-ST. The Audit Committee reviewed and deliberated on the proposals received from various audit firms, taking into consideration the requirements under Rules 712 and 715 of the Catalist Rules and the criteria for the evaluation and selection of external auditors contained in the Guidebook for Audit Committees in Singapore, including factors such as the adequacy of the resources, experience and track record of the auditing firm and the audit engagement partner, the audit firm's other audit engagements, the number and experience of supervisory and professional staff to be assigned to the audit and the fee proposal, the size and complexity of the Group, as well as the Audit Quality Indicators Disclosure Framework issued by ACRA. Management feedback was also sought as part of the deliberations by the Audit Committee. An objective approach was adopted throughout the process. After evaluating the above factors and taking into consideration the factors set out in Sections 2.2 to 2.4 below, the Audit Committee nominated and recommended FKT to the Board for appointment as the Auditors for FY2025, subject to Shareholders' approval to be obtained in a general meeting.

The Board took into account, inter alia, (i) the Audit Committee's recommendation, including the factors listed in Sections 2.2 to 2.4 below; and (ii) that the scope of audit services to be provided by FKT is comparable to the services currently provided by PwC. Accordingly, the Board is of the opinion that FKT meets the existing needs and audit requirements of the Company. The Board, in consultation with the Audit Committee, has nominated and recommended FKT to be appointed as the Auditors.

Pursuant to Rule 712(3) of the Catalist Rules and Section 205AF of the Companies Act, the appointment of FKT as the Auditors in place of PwC must be specifically approved by Shareholders in a general meeting.

LETTER TO SHAREHOLDERS

FKT has on 28 November 2024 given its written consent to act as auditors of the Company subject to Shareholders' approval being obtained at the forthcoming AGM for the Proposed Appointment of Auditors ("**FKT Consent Letter**"). A copy of the FKT Consent Letter is set out at Appendix A of this Addendum.

Accordingly, the retirement of PwC will take effect upon the conclusion of the forthcoming AGM, and the appointment of FKT as the Auditors will take effect upon the approval by the Shareholders at the AGM. FKT, if appointed, will hold office until the conclusion of the next AGM of the Company.

2.2 Information on FKT and the audit engagement partner

The information on FKT and the audit engagement partner provided below was provided to the Company by FKT and its representatives. The Directors have not conducted an independent review or verification of the accuracy of the statements and information below.

About FKT

Foo Kon Tan LLP, founded in 1968, is one of Singapore's most established and respected accountancy practices. Today, FKT, Chartered Accountants of Singapore and its associated companies provide a full range of assurance, tax and advisory services to listed companies, privately held businesses, not-for-profit organisations, and other public sector entities.

The firm helps clients navigate the ever-changing dynamics of the business and regulatory environments in the domestic and global market. Clients get a personal, hands-on services from the partners and senior people who have been and continue to be the hallmark of the FKT client experience.

The firm is a principal member of HLB International, a world-wide network of independent accounting firms and business advisers.

About the Audit Engagement Partner

Mr Ho Teik Tiong is the engagement partner of FKT, who will be assigned to the audit of the Group. Mr Ho Teik Tiong has more than 25 years of experience in the professional practice assisting clients in the public and private sectors and MNCs to align their growth strategies with their business risks. He also helped clients within the auditing profession to implement quality control policies and procedures under the SSQM 1 framework. His wealth of experience included four years as a reviewer and regulator in the Practice Monitoring Programme with Singapore's Accounting and Corporate Regulatory Authority (ACRA).

Mr Ho Teik Tiong started his career with one of the Big 4. He joined FKT in 1999 where his passion and dedication were recognised leading to several leadership roles in the assurance department. After 4 years in ACRA as the Deputy Head of the Practice Monitoring Division, he re-joined in 2012. He was the Head of Quality Control & Assurance team and oversees the implementation of quality control policies and procedures of the firm, and now the Head of Assurance. His experience as a professional services provider to clients and previously in ACRA's practice monitoring division means that clients will benefit as he draws on his depth of experience to identify, comprehend and provide meaningful advice which address the key business risks and operational issues facing his clients.

LETTER TO SHAREHOLDERS

His professional qualifications and memberships are as follows:

- Bachelor of Accountancy (Honours), Nanyang Technological University, Singapore
- Chartered Accountant of Institute of Singapore Chartered Accountants (ISCA)
- Fellow member, Association of Chartered Certified Accountants (ACCA)
- Member, Chartered Financial Institute (CFI)

For the audit of the Group, the audit engagement team will comprise the following professionals: one engagement quality reviewer, one engagement partner, one manager, one senior in-charge, audit associates and supported with a technical partner and if necessary, a team of professional auditor's expert comprising a director and a senior.

The Audit Committee had also considered the Audit Quality Indicators listed in the ACRA's Audit Quality Indicators Disclosure Framework in its selection of FKT as the Company's new Auditors.

The Audit Committee has enquired on whether Mr Ho Teik Tiong has been subject to the Practice Monitoring Programme review by ACRA. In this regard, the Audit and Risk Committee has noted that Mr Ho Teik Tiong has passed the Practice Monitoring Programme review by ACRA on his previous audit engagement and received no adverse feedback from previous exercise.

2.3 Requirements pursuant to Rule 712 of the Catalist Rules

FKT is an established firm in Singapore registered with ACRA. In compliance with Rules 712(1) and 712(2) of the Catalist Rules, the Audit Committee, for the reasons set out in Section 2.1 and having regard to the information provided by FKT on its firm and the audit engagement partner in Section 2.2 above, is of the view that FKT is a suitable auditing firm to meet the audit requirements of the Group.

In accordance with the requirements of Rule 712(3) of the Catalist Rules:

- (a) PwC has confirmed by way of a letter to FKT dated 9 December 2024 ("**Professional Clearance Letter**") that it is not aware of any professional reasons why FKT should not accept appointment as new auditors of the Company;
- (b) the Company confirms that there were no disagreements with PwC on accounting treatments within the last 12 months up to the date of this Addendum;
- (c) the Company confirms that it is not aware of any circumstances connected with the Proposed Appointment of Auditors that should be brought to the attention of the Shareholders which has not been disclosed in this Addendum;
- (d) the Company confirms that the specific reasons for the Proposed Appointment of Auditors are disclosed in Section 2.1 of this Addendum. The Proposed Appointment of Auditors is neither due to the dismissal of PwC nor PwC declining to continue to serve as auditors of the Company; and
- (e) the Company confirms that it is in compliance with Rules 712 and 715 of the Catalist Rules in relation to the appointment of FKT as its new Auditors.

LETTER TO SHAREHOLDERS

2.4 Requirements pursuant to Rule 715 of the Catalist Rules

Subject to Shareholders' approval of the Proposed Appointment of Auditors at the AGM to be held on 27 December 2024, FKT will be appointed as the Auditors in place of PwC. FKT will also be the Auditors for the respective significant Singapore-incorporated subsidiaries of the Company, being:

- (a) Asia HealthPartners Pte. Ltd.
- (b) Advanced Medicine Imaging Pte. Ltd.
- (c) Proton Therapy Pte. Ltd.

The remaining Singapore-incorporated subsidiaries of the Company (being Berjaya Investment Holdings Pte. Ltd., Advanced Medicine Oncology Pte. Ltd. and Advanced Medicine Radiopharmaceutical Pte. Ltd.) will remain audited by TY Teoh International LLP as there are minimal activities being carried out by the aforementioned subsidiaries. In accordance with Rule 716(1) of the Catalist Rules, the Board and the Audit Committee confirm that they are satisfied that such audit arrangements would not compromise the standard and effectiveness of the audit of the Company and the Group.

As at the Latest Practicable Date, the Company does not have any significant associated companies.

In view of the above, the Board confirms that Rule 715 of the Catalist Rules has been complied with.

2.5 Audit Committee's Recommendation

The Audit Committee has reviewed the Proposed Appointment of Auditors and recommends the appointment of FKT as the new Auditors, after taking into account, among other things:

- (a) the Audit Quality Indicators Disclosure Framework introduced by ACRA on the selection of auditor as well as the suitability and independence of FKT to meet the audit requirements of the Group;
- (b) the various factors set out in Sections 2.2 to 2.4 of this Addendum above;
- (c) neither FKT nor the engagement partner to be assigned to the audit of the Group has been the subject of any regulatory investigation or complaints;
- (d) FKT was selected for the Practice Monitoring Programme review by ACRA in 2019 with no adverse feedback. The incoming engagement partner has not yet been subject to any Practice Monitoring Programme review;
- (e) the scope of audit services to be provided by FKT is comparable to the services currently provided by PwC; and
- (f) compliance with the requirements of the relevant Catalist Rules.

LETTER TO SHAREHOLDERS

3. INTERESTS OF DIRECTORS AND SUBSTANTIAL SHAREHOLDERS

As at the Latest Practicable Date, the interests of the Directors and Substantial Shareholders in the capital of the Company are as follows:

	Direct Interest		Deemed Interest	
	Number of Shares	% ⁽¹⁾	Number of Shares	% ⁽¹⁾
Directors				
Khoo Tiam Hock Vernon ⁽²⁾	–	–	150,000	0.01
Dr Djeng Shih Kien ⁽³⁾	65,750,000	6.27	35,142,710	3.35
Yeo Seng Lye Paul	931,675	0.09	–	–
Vivienne Cheng Chi Fan	–	–	–	–
Dato' Lee Kok Chuan ⁽⁴⁾	4,375,000	0.42	4,328,100	0.41
Gurdip Singh S/O Boor Singh	1,000,000	0.10	–	–
Sumei Shum	44,200	0.004	–	–
Substantial Shareholders				
Espeetex Sdn. Bhd. ⁽⁵⁾	249,003,148	23.76	–	–
Berjaya Leisure (Cayman) Limited ⁽⁵⁾	149,943,970	14.31	–	–
Crescendas Land Corporation Pte. Ltd. ⁽⁶⁾	110,522,568	10.55	–	–
Berjaya Land Berhad ⁽⁵⁾	–	–	149,943,970	14.31
Berjaya Group Berhad ⁽⁵⁾	–	–	403,547,118	38.50
Berjaya Corporation Berhad ⁽⁵⁾	–	–	403,547,118	38.50
Tan Sri Dato' Seri Vincent Tan Chee Yioun ⁽⁵⁾	–	–	403,947,118	38.54
Singapore Capital Incorporation Pte. Ltd. ⁽⁶⁾	–	–	110,522,568	10.55
Euphonia Pte. Ltd. ⁽⁶⁾	–	–	110,522,568	10.55
Lawrence Leow Chin Hin ⁽⁶⁾	–	–	110,522,568	10.55

Notes:

- (1) Based on the total number of existing Shares (excluding treasury shares and subsidiary holdings) of 1,048,099,074 Shares as at the Latest Practicable Date.
- (2) Mr Khoo Tiam Hock Vernon is deemed interested in all the Shares held by his spouse, Madam Lim Tiow Bin.
- (3) Dr Djeng Shih Kien is also a director and shareholder who holds approximately 59.99% of the total number of issued shares in the capital of Orthodontic & Dental Supplies Pte Ltd. Accordingly, Dr Djeng Shih Kien is deemed to have an interest in all the Shares held by the following parties under Section 7 of the Companies Act and Section 4 of the SFA:
 - (i) 14,125,000 Shares held by his spouse, Dr Ko Siew Lan; and
 - (ii) 21,017,710 Shares held by Orthodontic & Dental Supplies Pte Ltd.

LETTER TO SHAREHOLDERS

- (4) Dato' Lee Kok Chuan, a Non-Executive and Non-Independent Director of the Company, as well as a shareholder of the Company, is also a director and shareholder who holds approximately 27.42% of the total number of Issued shares in the capital of Dynamic Milestone Sdn Bhd. Accordingly, Dato' Lee Kok Chuan is deemed to have an interest in all the Shares held by Dynamic Milestone Sdn Bhd under Section 7 of the Companies Act and Section 4 of the SFA, being 4,328,100 Shares.

- (5) As at the Latest Practicable Date, Espeetex Sdn. Bhd. has an aggregate interest in 249,003,148 Shares, of which 131,878,309 Shares are held via a nominee account of UOB Kay Hian Private Limited.

As at the Latest Practicable Date, Berjaya Leisure (Cayman) Limited has an aggregate interest in 149,943,970 Shares, of which 74,971,985 Shares are held via a nominee account of UOB Kay Hian Private Limited.

As at the Latest Practicable Date, Berjaya Group Berhad holds 100.00% of the total number of issued shares in the capital of Espeetex Sdn. Bhd. and Bizurai Bijak (M) Sdn Bhd ("**Bizurai**"). Berjaya Group Berhad also has an aggregate interest (direct and indirect) in approximately 64.99% of Berjaya Land Berhad, which in turn holds 100.00% of the total number of issued shares in the capital of Berjaya Leisure (Cayman) Limited. Berjaya Corporation Berhad holds 100.00% of the total number of issued shares in the capital of Berjaya Group Berhad and has an aggregate interest (direct and indirect) in approximately 73.54% of Berjaya Land Berhad. As at the Latest Practicable Date, Tan Sri Dato' Seri Vincent Tan Chee Yioun has an aggregate interest (direct and indirect) in approximately 16.17% of Berjaya Corporation Berhad.

Accordingly, Berjaya Group Berhad, Berjaya Corporation Berhad, and Tan Sri Dato' Seri Vincent Tan Chee Yioun are deemed to have an interest in all the Shares held by Espeetex Sdn. Bhd., Bizurai, and Berjaya Leisure (Cayman) Limited under Section 7 of the Companies Act and Section 4 of the SFA. As at the Latest Practicable Date, Bizurai has a direct interest in 4,600,000 Shares, representing 0.44% shareholding interest in the Company.

Tan Sri Dato' Seri Vincent Tan Chee Yioun is deemed interested in all the Shares held by Espeetex Sdn. Bhd., Bizurai, and Berjaya Leisure (Cayman) Limited as he is a controlling shareholder of Berjaya Corporation Berhad. Tan Sri Dato' Seri Vincent Tan Chee Yioun is also deemed interested in all the Shares held by Convenience Shopping (Sabah) Sdn Bhd ("**CSSB**") under Section 7 of the Companies Act and Section 4 of the SFA. As at the Latest Practicable Date, CSSB, a wholly-owned subsidiary of 7-Eleven Malaysia Holdings Berhad, has a direct interest in 400,000 Shares, representing 0.04% shareholding interest in the Company.

In addition, Berjaya Land Berhad is deemed to have an interest in all the Shares held by Berjaya Leisure (Cayman) Limited under Section 7 of the Companies Act and Section 4 of the SFA.

- (6) As at the Latest Practicable Date, the shareholders of Crescendas Land Corporation Pte. Ltd. are (i) Singapore Capital Incorporation Pte. Ltd., (ii) Winfred Pte. Ltd., and (iii) Lawrence Leow Chin Hin, who hold 81.66%, 12.61% and 5.73% of the total number of issued shares in the capital of Crescendas Land Corporation Pte. Ltd., respectively. Euphonia Pte. Ltd. holds 100.00% of the total number of issued shares in the capital of Singapore Capital Incorporation Pte. Ltd..

Lawrence Leow Chin Hin is (i) the Chairman and Chief Executive Officer of Crescendas Land Corporation Pte. Ltd., and (ii) a director of Singapore Capital Incorporation Pte. Ltd.. He is also a director and shareholder who holds 100.00% of the total number of issued shares in the capital of (i) Winfred Pte. Ltd., and (ii) Euphonia Pte. Ltd.

Accordingly, Singapore Capital Incorporation Pte. Ltd., Euphonia Pte. Ltd. and Lawrence Leow Chin Hin are deemed to have an interest in all the Shares held by Crescendas Land Corporation Pte. Ltd. under Section 7 of the Companies Act and Section 4 of the SFA.

None of the Directors or the Substantial Shareholders, as well as their respective associates, have any interest, whether direct or indirect (other than through their respective shareholding interest (if any), employment and/or directorship (as applicable) in the Company) in the Proposed Appointment of Auditors.

4. DIRECTORS' RECOMMENDATION

Having fully considered, *inter alia*, the rationale and the information relating to the Proposed Appointment of Auditors as set out in this Addendum and the recommendation of the Audit Committee, the Directors are of the opinion that the Proposed Appointment of Auditors is in the best interests of the Company. Accordingly, the Directors recommend that the Shareholders vote in favour of the Ordinary Resolution 7 set out in the Notice of AGM relating to the Proposed Appointment of Auditors to be proposed at the AGM.

LETTER TO SHAREHOLDERS

5. DIRECTORS' RESPONSIBILITY STATEMENT

The Directors collectively and individually accept full responsibility for the accuracy of the information given in this Addendum and confirm after making all reasonable enquiries, that to the best of their knowledge and belief, this Addendum constitutes full and true disclosure of all material facts about the Proposed Appointment of Auditors, the Company and its subsidiaries, and the Directors are not aware of any facts the omission of which would make any statement in this Addendum misleading. Where information in this Addendum has been extracted from published or otherwise publicly available sources or obtained from a named source, the sole responsibility of the Directors has been to ensure that such information has been accurately and correctly extracted from those sources and/or reproduced in this Addendum in its proper form and context.

6. DOCUMENTS FOR INSPECTION

The following documents are available for inspection by Shareholders at the registered office of the Company at 1 Biopolis Drive, #02-01 Amnios, Singapore 138622 during normal business hours from the date of this Addendum up to and including the date of the forthcoming AGM:

- (i) the constitution of the Company;
- (ii) the annual report of the Company for the financial year ended 30 June 2024;
- (iii) the letter of withdrawal of consent to act from PwC dated 9 December 2024;
- (iv) PwC's Professional Clearance Letter to FKT dated 9 December 2024; and
- (v) the FKT Consent Letter dated 10 December 2024.

Yours faithfully

For and on behalf of the Board

Singapore Institute of Advanced Medicine Holdings Ltd.

Dr Djeng Shih Kien

Executive Director and Chief Executive Officer

APPENDIX A – FKT CONSENT LETTER



Foo Kon Tan LLP • 1 Raffles Place, One Raffles Place Tower 2 #04-61 • Singapore 048616
T +65 6336 3355 F +65 6337 2197 E ftk@fookontan.com www.fookontan.com

Our ref: HTT/

Private & Confidential

Date: 10 December 2024

The Board of Directors

Singapore Institute of Advanced Medicine Holdings Ltd (the “Company”)

1 Biopolis Dr
#02-01 Amnios
Singapore 138622

Dear Sirs

CONSENT TO ACT AS AUDITOR

We thank you for your letter dated 27 November 2024 indicating your nomination to appoint us as your statutory auditor for the Company and its Singapore incorporated subsidiaries namely; Asia HealthPartners Pte Ltd, Advance Medicine Imaging Pte Ltd and Proton Therapy Pte Ltd.

Subject to the approval by the Accounting and Corporate Regulatory Authority (“ACRA”) on the incumbent auditor’s resignation in accordance with Section 205AB of the Companies Act 1967 and the subsequent shareholders’ approval at the Extraordinary General Meeting of the Company, to be convened on a later date, we hereby consent to act as the auditors of the Company and the Singapore incorporated subsidiaries, for the current financial year ending 30 June 2025 and future years until such consent is withdrawn by us.

Yours faithfully

A handwritten signature in black ink that reads "Foo Kon Tan LLP".

Foo Kon Tan LLP
Public Accountants and Chartered Accountants
Singapore

Chartered Accountants of Singapore

Foo Kon Tan LLP (UEN: T10LL0002B) is an accounting limited liability partnership registered in Singapore under the Limited Liability Partnerships Act (Chapter 163A).



This page has been intentionally left blank.

